Background and Objectives: The objective of this study was to evaluate in vivo two new biomaterials for
bone substitution aiming to determining their ability to enable bone neoformation in critical-size defects in
rats’ calvaria.
Methods: Synthetic hydroxyapatite were developed – Pure hydroxyapatite (HaP) and Hydroxyapatite with
collagen (HCol). The third synthetic hydroxyapatite used as a comparing element was the commercial
hydroxyapatite Alobone® (HaAl). Sixty Wistar rats divided randomly into four groups (Group 1, HaP;
Group 2, HaCol; Group 3, HaAl and Group 4, Control). Critical size defects of 8mm were performed in the
calvaria, and the three biomaterials were implanted. All groups also received a collagen membrane.
Results: On day 30, the inflammatory response on the defect was practically absent in all groups, mainly
when compared to the period of 7 days. Some areas of bone neoformation were seen. There was
predominance of osteoblasts, osteocytes, and macrophages in lower amounts. Regarding the radiographic
aspect, after 30 days, a marked biodegradation of the hydroxyapatite and signs of bone neoformation were
observed.
Conclusions: It was concluded that the results of our study in vivo can be used as a preliminary source of
information about biocompatibility, biodegradability, and bone neoformation from the implant of new
biomaterials in vivo.